|
Scientific Summits Meeting Live webinar
5 June 2020 – 15h30 to 19h
Expired
This course is expired
Scientific Summits
Chapters
-
1Introduction
-
2Poll: For the Urologists, select the correct answer:
-
1The sense and non-sense of retzius-sparing ralp
-
2Poll: For the urologists, select the correct answer
-
3Discussion: The sense and non-sense of retzius-sparing ralp
-
4Poll: In patients with high-risk PCa
-
5Updated results of high-dose rate brachytherapy in high-risk prostate cancer
-
6Poll: In patients with high-risk PCa (2)
-
7Discussion: updated results of high-dose rate brachytherapy in high-risk prostate cancer
-
8Poll: Adjuvant radiotherapy after prostatectomy should be completely abandoned!
-
9Postoperative radiotherapy after prostatectomy: is early salvage rt the new standard? what should we learn from radicals?
-
10Poll: Adjuvant radiotherapy after prostatectomy should be completely abandoned! - after
-
11Discussion: postoperative radiotherapy after prostatectomy: is early salvage RT the new standard? What should we learn from radicals?
-
12Poll: For the urologists attending this virtual scientific summits, have you ever performed a radical prostatectomy in M1 PCa?
-
13The place of surgery in MHSPC
-
14Discussion: The place of surgery in MHSPC
-
15Poll: If we perform germline and/or somatic testing in metastatic prostate cancer. how common are BRCA+ (or BRCA like) mutations found?
-
16Poll: In which patients do we expect the best response to PARP inhibitors?
-
17Development and clinical implementation of PARP-inhibitors in PCA management
-
18Discussion: Development and clinical implementation of PARP-inhibitors in PCA management
-
1Introduction
-
2Poll: A nephrectomy as cytoreductive treatment in M+ patients
-
3Time to abandon all cytoreductive nephrectomies?
-
4Discussion: Time to abandon all cytoreductive nephrectomies?
-
5The changing first line treatment paradigm in metastatic clear cell renal cell cancer
-
6Poll: A nephrectomy as cytoreductive treatment in M+ patients - after
-
1Introduction
-
2The expanding role of rt in all stages of urothelial cancer
-
3Poll: Regarding trimodality bladder preserving therapy (TMT) as primary therapy in MIBC, which of the following conditions is a contra-indication?
-
4Poll: Compared to adjuvant chemotherapy alone, current best evidence shows that adding adjuvant radiotherapy improves:
-
5Discussion: The expanding role of rt in all stages of urothelial cancer
-
6Poll: Choose 1 answer
-
7Ongoing trial in MIBC
-
8Poll: Neo-adjuvant cisplatinum-based combination chemotherapy remains the gold standard in MIBC
-
9Discussion: Ongoing trial in MIBC
-
10Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
-
11Poll: Neo-adjuvant pembrolizumab before radical cystectomy in pure-01 study. which statement is correct
-
12Discussion: Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
-
13Discussion 2: Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
-
1Wrapup from the chairman
Chapters
-
1Introduction
-
2Poll: For the Urologists, select the correct answer:
-
1The sense and non-sense of retzius-sparing ralp
-
2Poll: For the urologists, select the correct answer
-
3Discussion: The sense and non-sense of retzius-sparing ralp
-
4Poll: In patients with high-risk PCa
-
5Updated results of high-dose rate brachytherapy in high-risk prostate cancer
-
6Poll: In patients with high-risk PCa (2)
-
7Discussion: updated results of high-dose rate brachytherapy in high-risk prostate cancer
-
8Poll: Adjuvant radiotherapy after prostatectomy should be completely abandoned!
-
9Postoperative radiotherapy after prostatectomy: is early salvage rt the new standard? what should we learn from radicals?
-
10Poll: Adjuvant radiotherapy after prostatectomy should be completely abandoned! - after
-
11Discussion: postoperative radiotherapy after prostatectomy: is early salvage RT the new standard? What should we learn from radicals?
-
12Poll: For the urologists attending this virtual scientific summits, have you ever performed a radical prostatectomy in M1 PCa?
-
13The place of surgery in MHSPC
-
14Discussion: The place of surgery in MHSPC
-
15Poll: If we perform germline and/or somatic testing in metastatic prostate cancer. how common are BRCA+ (or BRCA like) mutations found?
-
16Poll: In which patients do we expect the best response to PARP inhibitors?
-
17Development and clinical implementation of PARP-inhibitors in PCA management
-
18Discussion: Development and clinical implementation of PARP-inhibitors in PCA management
-
1Introduction
-
2Poll: A nephrectomy as cytoreductive treatment in M+ patients
-
3Time to abandon all cytoreductive nephrectomies?
-
4Discussion: Time to abandon all cytoreductive nephrectomies?
-
5The changing first line treatment paradigm in metastatic clear cell renal cell cancer
-
6Poll: A nephrectomy as cytoreductive treatment in M+ patients - after
-
1Introduction
-
2The expanding role of rt in all stages of urothelial cancer
-
3Poll: Regarding trimodality bladder preserving therapy (TMT) as primary therapy in MIBC, which of the following conditions is a contra-indication?
-
4Poll: Compared to adjuvant chemotherapy alone, current best evidence shows that adding adjuvant radiotherapy improves:
-
5Discussion: The expanding role of rt in all stages of urothelial cancer
-
6Poll: Choose 1 answer
-
7Ongoing trial in MIBC
-
8Poll: Neo-adjuvant cisplatinum-based combination chemotherapy remains the gold standard in MIBC
-
9Discussion: Ongoing trial in MIBC
-
10Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
-
11Poll: Neo-adjuvant pembrolizumab before radical cystectomy in pure-01 study. which statement is correct
-
12Discussion: Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
-
13Discussion 2: Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
-
1Wrapup from the chairman